BioMarin Pharmaceutical (BMRN) is on the list of such stocks currently recommended by our proprietary system. In addition to a favorable Growth Score, it carries a top Zacks Rank. Research shows ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

BioMarin Pharmaceutical (BMRN ... A positive trend is a plus here. Empirical research shows that there is a strong correlation between trends in earnings estimate revisions and near-term stock ...

BioMarin's has signed the first contract with an insurer in Germany for Roctavian, its recently approved gene therapy for haemophilia A, as it tests out its outcomes-based agreement (OBA ...

BioMarin Pharmaceutical (BMRN ... A positive trend is a plus here. Empirical research shows that there is a strong correlation between trends in earnings estimate revisions and near-term stock ...

In this article, we are going to take a look at where BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) stands against the other healthcare stocks. McKinsey reported that, since 2019, the US healthcare ...

A significant part of BioMarin’s growth strategy involves Voxzogo, which has shown strong sales performance. Although facing competition, Voxzogo stands out due to its high compliance rate ...

Wedbush analyst Yun Zhong maintained a Buy rating on BioMarin Pharmaceutical (BMRN – Research Report) today and set a price target of $94.00. Discover outperforming stocks and invest smarter ...

BioMarin Pharmaceutical (BMRN) is on the list of such stocks currently recommended by our proprietary system. In addition to a favorable Growth Score, it carries a top Zacks Rank. Studies have ...